Valeant Pharmaceuticals Management Is Doing Commendable Job But Key Challenges Remain, Says BTIG

Valeant Pharmaceuticals (NYSE:VRX) is on the road to redemption after a robust third quarter earnings showcase has seen the company gain around 10% in value in the past two days. BTIG analyst¬†Tim Chiang¬†calls the comeback kid of the Street’s leadership simply stellar, but says glaucoma drug Vyzulta needs to succeed.

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts